JOURNAL OF INTERNATIONAL CRISIS AND RISK COMMUNICATION RESEARCH
ISSN: 2576-0017
2024, VOL 7, NO S7

# Nanotechnology in Drug Delivery: Overcoming Biological Barriers and Enhancing Targeted Therapy

**Abdullah Saud Nahar Alotaibi[1], Abdulrhman Edhah Alkhudidy[2], Abdullah muneerowimer Almutairi[3], Ebtisam Ali Hassan Aljaizani[3], Mohammed Mohsen Bakheet Alharbi[4], Fahad Bakahtsaad Alghamdi[5], Mousa Rabei alzahrani[5], Mohammed Ahmed Alhothifi Alamri[6], Abdulrahman Awadh Saeed Alqahtani[6], Majid Abdullah Hassan Alghamdi[7], Fahad Abbas Mohammed Hamzah[8]**

1. Pharmacist Technician, Al-Dawadmi General Hospital, Saudi Arabia.
2. Pharmacy Technician, Al kur Shaddad Health Center, Saudi Arabia.
3. Pharmacist, Medical Supply Department at the Ministry of Health, Saudi Arabia.
4. Assistant Pharmacist, Ibin Sina Hospital Ministry of Health, Makkah, Saudi Arabia.
5. Pharmacy Technician, King Fahad Hospital Albaha, Saudi Arabia.
6. Pharmacist, King Fahad Hospital Albaha, Saudi Arabia.
7. Pharmacy technician, King Abdulaziz Hospital, Saudi Arabia.
8. Pharmacy technician, King Abdulaziz Hospital, Jeddah, Saudi Arabia.

**Background:**Nanotechnology is revolutionizing the pharmaceutical sciences by providing new ways to deliver drugs to the body. Drugs can have their bioavailability, solubility, and targeting capabilities improved with the use of nanoparticles and other nanoscale materials. New drug delivery systems made possible by nanotechnology have the potential to enhance therapeutic results while reducing unwanted side effects. Doxil® and Abraxane® are just two of the many FDA-approved nanomedicines that highlight how this technology has the potential to transform conventional medicine for the treatment of cancer, neurological disorders, and infectious diseases.
**Aim:**To better understand how to construct nanoparticles and nanocarriers to increase therapeutic efficacy, decrease toxicity, and offer more controlled and targeted distribution to tissues or cells, researchers are investigating the use of nanotechnology in drug delivery. Research into targeted drug delivery methods, assessments of nanomedicines' therapeutic potential, and resolution of issues related to the development and implementation of therapies based on nanotechnology are all part of this field. Further, we hope to bring attention to the promising future of nanomedicine by showcasing its potential applications in areas such as sustainable and individualized healthcare, the use of biodegradable materials, and the integration of artificial intelligence.
**Conclusion:**By allowing for more efficient, accurate, and tailored therapeutics, nanotechnology may completely alter drug delivery methods. Improved medication solubility, bioavailability, and therapeutic effectiveness with reduced systemic toxicity and adverse effects are all possible thanks to nanomedicines, which are made possible by advancements in nanoparticle design and drug encapsulation. Future answers for sustainable and personalized treatment may lie in the integration of artificial intelligence, advancements in biodegradable materials, and the creation of multifunctional theranostic nanocarriers, despite obstacles including high development costs and safety concerns. Researchers are hopeful that nanotechnology will usher in a new age of highly targeted, efficient, and less intrusive medicines, vastly improving treatment outcomes for a variety of ailments.
**Keywords:**Immuno-oncology, Personalized Cancer Therapy, Nanoparticle-mediated Gene Therapy

## Introduction

The use of nanotechnology has greatly improved medication delivery, especially in removing biological obstacles to treatment. Nanoparticles, which can be anywhere from 1 to 100 nanometers in size, have the potential to revolutionize therapeutic interventions by increasing their solubility, bioavailability, and stability while allowing for controlled and targeted release. The BBB, the tumor microenvironment, and immune system responses are some of the biological obstacles that pose a significant threat to drug delivery. By manipulating their size and shape, nanoparticles can bypass these obstacles and transport medications to the sites of injury with little risk to the central nervous system. For instance, by leveraging specialized surface features like lipophilicity or receptor-mediated endocytosis, nanocarriers developed for brain-targeting applications can traverse the blood-brain barrier (BBB), which is ordinarily impervious to most medications.[1]

Additionally, nanoparticles make tumor-targeted therapy possible through the Enhanced Permeability and Retention (EPR) effect, which allows nanoparticles to selectively aggregate in tumor tissue due to characteristics of the tumor vasculature (such as leaky blood vessels). Nanoparticles can reduce side effects by making better use of this method to deliver chemotherapeutic drugs to cancer cells with less damage to healthy tissues. In addition, theranostics allows for ongoing tracking of medication distribution and therapeutic results using a single nanocarrier, allowing for adaptive treatment modifications in response to diagnostic data.[2]

A growing number of diseases, including cancer, neurological disorders, infectious diseases, autoimmune disorders, and cardiovascular diseases, are finding ways to overcome biological barriers with the help of nanotechnology. Patients are more likely to take their medications as prescribed and experience better outcomes from their therapies when nanoparticles are tailored to increase drug solubility, target certain receptors or antigens, and provide controlled or sustained release of therapeutic substances.[3]

Nanotechnology shows a lot of potential for the future of medication administration. The effectiveness of treatments and the reduction of dangers can be further improved with the development of increasingly complex nanoparticles that integrate targeted delivery, controlled release, and diagnostic capabilities. Optimizing these systems for personalized medicine, which offers tailored medicines that fit the needs of patients, will also rely on the integration of nanotechnology, biomaterials, and artificial intelligence. Before nanomedicine can reach its full potential in everyday clinical practice, however, issues with production scalability, regulatory clearance, and long-term safety need to be resolved.[4]

A game-changer in the field of pharmaceutical sciences, nanotechnology for targeted drug delivery is altering the way drugs are given and absorbed by the body. Drugs can be administered directly to specific cells or tissues using nanoscale carriers as dendrimers, polymeric nanoparticles, or liposomes. This improves efficacy and minimizes negative effects. Methods such as active targeting, in which ligands direct nanoparticles to certain receptors, and passive targeting, which takes advantage of the increased permeability of sick tissues, allow for such precision.[5]

This technology has the potential to improve results while reducing systemic problems in a variety of important fields, such as cancer treatment, neurological disorders, and infectious diseases. Production costs, possible toxicity, and regulatory difficulties are some of the challenges that need to be solved, despite its promise. Innovative solutions for complicated medical problems are emerging from the convergence of diagnosis and therapy made possible by nanotechnology, which is rapidly shaping the future of personalised medicine.[6]

**Nanotechnology in Medicine**

Structures, devices, and systems on the nanoscale scale (1-100 nanometers) are the focus of nanotechnology, a subfield of engineering and science. When compared to their larger-scale equivalents, materials at this size have distinct physical, chemical, and biological characteristics. Because of these characteristics, nanotechnology has a lot of potential in many fields, including medicine. By paving the way for advancements in regenerative medicine, drug delivery, and diagnostics, nanotechnology is revolutionizing the healthcare industry. Nanocarriers, including liposomes and nanoparticles, have several uses, one of the most important of which is targeted drug delivery, which involves delivering medications just to sick tissues while avoiding healthy ones.[7]

Furthermore, imaging agents and nanosensors are examples of highly sensitive diagnostic tools that make use of nanotechnology to enable earlier and more precise illness identification. Wound healing, bioengineered tissues, and vaccine research (using lipid nanoparticle technology, for example, in mRNA vaccines) are some other potential uses for nanomaterials. The field of modern medicine is being transformed by nanotechnology, which takes advantage of the distinct characteristics of nanomaterials.[8]

**Historical overview of its integration into drug delivery systems.**

Innovations in biomedical engineering and materials science have spurred substantial progress in the last several decades toward fully integrating nanotechnology into medication delivery systems. The initial major stride toward drug delivery by nanoparticles occurred in the 1960s, when the concept of drug-encapsulating vesicles called liposomes was initially proposed. Later on, liposomes' capacity to increase the solubility and stability of drugs led to their use in cancer treatment and other medical domains.[9]

Polymeric nanoparticles, dendrimers, and metallic nanoparticles were developed during the 1990s and early 2000s, causing a surge in nanotechnology. Thanks to these advancements, medication release could be better managed, targeting could be enhanced, and systemic toxicity could be decreased. Passive targeting, which involves guiding nanoparticles to tumor tissues via the Enhanced Permeability and Retention (EPR) effect, first appeared at this time.To bind exclusively to sick cells, researchers in the 2010s investigated active targeting strategies that involved attaching ligands, antibodies, or peptides to nanocarriers. At the same time, the clinical potential of nanotechnology was brought to light by the approval of nanomedicines such as Doxil® (liposomal doxorubicin) and Abraxane® (albumin-bound paclitaxel).[10]

Drug delivery tactics have been further optimized in recent years due to advancements in stimuli-responsive systems, smart nanocarriers, and theranostics, which combines therapy and diagnostics. Lipid nanoparticles' efficacy in COVID-19 mRNA vaccines has established nanotechnology as a cornerstone of contemporary medicine, opening the door to its expanded use in precision and individualized healthcare.[11]

**Types of Nanocarriers for Drug Delivery**

Phospholipid bilayers encase an aqueous core in liposomes, which are spherical vesicles. These structures are biocompatible and have medicinal potential since they resemble real biological membranes. Since their description in the 1960s, liposomes have risen to prominence as a leading nanocarrier for drug delivery, receiving much research and practical application. Because of their unusual structure, they can encapsulate medications with both hydrophilic and hydrophobic properties. Transporting a diverse variety of therapeutic medicines is made possible by the ability to house water-soluble pharmaceuticals in the aqueous core and hydrophobic drugs in the lipid bilayer. Liposomes are highly advantageous for medications that are not very water-soluble since they encapsulate the molecule, make it more stable, and increase its solubility.[12]

The capacity to tailor liposomes for specific medication delivery is a major benefit. To improve therapeutic efficacy and decrease off-target effects, ligands like antibodies, peptides, or sugars can be attached to the surface of liposomes, allowing them to be directed to certain cells or tissues. Another advantage of liposome engineering is the ability to have them respond to changes in environmental factors such as pH or temperature by releasing their contents. Liposomal formulations like Ambisome® (liposomal amphotericin B) and Doxil® (liposomal doxorubicin) have shown efficacy in treating fungal infections and cancer, respectively, in clinical trials. The importance of liposomes in the advancement of medication delivery systems based on nanotechnology has been brought to light by these advances.[13]

**Nano emulsions and Micelles: Enhanced solubility for poorly soluble drugs**

The size of the oil phase, the water phase, and the surfactants in a nanoemulsion usually vary between 20 and 200 nanometers, making it a sort of colloidal dispersion. To improve the absorption and effectiveness of hydrophobic (lipophilic) medications, these emulsions aid to solubilize them. They are stable systems from a thermodynamic perspective.Nanoemulsionscan encapsulate pharmaceuticals with different solubility properties, allowing for improved bioavailability of substances that are not particularly soluble.Nanoemulsions allow for precise dosing control by adjusting the surfactant composition and characteristics. Oral, parenteral, and topical drug delivery methods all make use of nanoemulsions, and they're especially useful for meds that need to be absorbed more quickly or released over a longer period. They are also used for hormones, vitamin, and antioxidant administration.[14]

When surfactants are dissolved in water, they self-assemble into micelles, which are amphiphilic nanostructures with hydrophilic and hydrophobic components. The core-shell configuration of surfactant molecules is formed by the hydrophobic "tails" clustering inward and the hydrophilic "heads" facing outward. Micelles usually have a size between ten and one hundred nanometers. Micelles are a great way to improve the solubility of lipophilic medications that aren't very water-soluble. This makes them easier to disperse and absorb in watery settings, such as the GI tract.[15]

Micelles can be beneficial for targeted drug delivery to sick locations like tumors by functionalizing their outer shell with specific ligands or antibodies. This allows them to target select cells or tissues. Micelles find extensive usage in the delivery of many medications, such as those for cancer treatment, infection prevention, and gene therapy. In intravenous formulations, they are also crucial for improving the delivery of lipophilic drugs.[16]

**Advantages of Micelles and Nanoemulsions**

The solubility of medications is enhanced usingnanoemulsions and micelles, which improves their absorption and therapeutic efficacy.

These systems can lessen harmful drug side effects by increasing bioavailability and focusing on tissues. Their adaptability allows for a wide range of drug delivery techniques, as they may be designed to accommodate both hydrophobic and hydrophilic medicines. Reducing the frequency of administration improves patient compliance through controlled release, which is possible with both methods.[17]

**Mechanism of Targeted Drug Delivery**

By delivering medications to cells or tissues, targeted drug delivery systems hope to increase therapeutic efficacy while decreasing negative effects. Multiple methods, including passive and active targeting as well as stimuli-responsive devices, contribute to this level of accuracy. Because tumors and other diseased tissues have blood arteries that are more permeable and less efficient at draining, passive targeting takes advantage of this fact to its advantage by concentrating nanoparticles in these areas, a result known as the Enhanced Permeability and Retention (EPR). Nanoparticles' ability to passively target tumors is a typical feature in cancer therapy.[18]

On the other hand, active targeting guarantees extremely selective medication delivery by modifying nanoparticles with molecules such as ligands, antibodies, or peptides that attach to receptors on the surface of sick cells. When it comes to targeting cancer cells that overexpress specific receptors, like HER2 or folate receptors, this method is incredibly useful. Lastly, stimuli-responsive methods make use of either internal or external variables, including changes in temperature, light, enzyme activity, or pH, to initiate the release of the medication capsule.[19]

While hyperthermia is commonly employed in cancer therapy, pH-sensitive nanoparticles can release their payload only in tumors, while temperature-sensitive systems can release medications only subjected to heat. Therapeutic efficacy and the reduction of undesired side effects are both improved by these systems, which permit more precise and controlled drug delivery.[20]

With its ability to administer drugs more precisely and efficiently, targeted drug delivery systems are showing great promise in many different therapeutic domains, especially in the treatment of complicated disorders. One of the most well-known uses of nanoparticles is in cancer therapy, where they are employed to transport chemotherapeutic medicines straight to tumor cells while reducing collateral damage to healthy tissues in the vicinity. This method improves the drug's efficacy while simultaneously decreasing the adverse effects and systemic toxicity that are typical of conventional chemotherapy. Through passive targeting (through the EPR effect) or active targeting with specific ligands that attach to cancer cell receptors, nanoparticles can be made to accumulate in tumors, enhancing the precision of medication administration.[21]

The blood-brain barrier (BBB) is a selective permeability barrier that serves to protect the brain from potentially dangerous chemicals but also hinders the effective delivery of drugs, making it a significant obstacle in the treatment of neurological illnesses. There is hope that nanoparticles can bypass the blood-brain barrier and transport medications straight to the brain. Due to the ineffectiveness of conventional medication delivery systems, this is of utmost importance un the treatment of diseases such as Alzheimer's, Parkinson's, and brain cancers. By manipulating their surfaces or making use of inherent transport processes, nanocarriers such solid lipid nanoparticles, polymeric nanoparticles, and liposomes can be engineered to traverse the blood-brain barrier (BBB).[22]

An increasingly major issue in infectious disease public health is the proliferation of microorganisms that are resistant to antibiotics. To improve treatment efficacy and decrease the possibility of resistance, researchers are investigating nanoparticles to transport antibiotics directly to sites of infection. One example is the use of silver and other metallic nanoparticles in targeted medication delivery systems, which can amplify their inherent antibacterial capabilities. More antibiotic concentration at the site of infection with less systemic adverse effects is possible with these methods because they deliver antibiotics to bacterial cells more efficiently.[23]

Lastly, nanocarriers are essential in gene therapy for transporting DNA, RNA, or gene-editing tools like CRISPR-Cas9 to specific cells. A potential approach of preserving genetic material, delivering it into cells, and ensuring regulated release is the use of nanoparticles. This application holds great promise for the advancement of personalized medicine and the treatment of genetic illnesses. By engineering nanoparticles to transport therapeutic genes to damaged cells, precise and targeted treatments can be achieved. More efficient, less intrusive, and highly targeted treatments across a variety of disorders may be possible with the help of nanotechnology's medical applications.[24]

**Benefits of Nanotechnology in Drug Delivery**

When it comes to drug distribution, nanotechnology has a lot of great advantages that can make treatments safer and more effective. The improved solubility and bioavailability of medications, especially those with low water solubility, is a major benefit. Encapsulating hydrophobic medications in nanocarriers like micelles, nanoparticles, or liposomes makes them more soluble in water, which improves their absorption in the body. Because nanocarriers can help achieve therapeutic concentrations with smaller doses, greatly decreasing the requirement for high drug amounts and boosting the overall effectiveness of the treatment, this is especially helpful for drugs with low bioavailability.[25]

Systemic toxicity and adverse effects are decreased, which is another big plus. Common adverse effects of conventional drug delivery systems include nausea, lethargy, and organ toxicity due to excessive drug concentrations in healthy tissues. On the other hand, nanocarriers can be engineered to zero in on cells or tissues, delivering the medication straight to the tumor or infection location. This specific method enhances the therapeutic index while decreasing adverse effects by limiting medication exposure to healthy tissues. To further improve therapy efficacy and control, nanoparticles can shield medications from metabolism and degradation.[26]

Another significant advantage of medicine delivery based on nanotechnology is improved patient compliance. Patients may not adhere to treatment regimens when they are required to take many medications at once, which can be a nuisance. The medicine can be released gradually over a long period of time using nanocarriers that have been developed for controlled release. This makes it easier for the patient to take their medication as directed, which in turn increases the likelihood that they will adhere to their treatment plans. Chronic diseases require long-term care, therefore the ability to establish stable therapeutic levels without frequent administration is very useful.[27]

Nanotechnology is a potent tool in contemporary pharmacological treatment because it increases bioavailability, decreases toxicity, and improves patient compliance with medication delivery.Nanotechnology has many potential uses, but there are also certain restrictions and difficulties associated with using it to deliver drugs. The high expense of development and production is one of the primary hurdles. Complex and costly procedures are frequently involved in the synthesis, formulation, and scaling-up of nanocarriers such as liposomes, nanoparticles, and others. Raw material costs, the price of necessary technology and equipment, and the time and effort put into labor-intensive production processes to guarantee quality and consistency all factor into this. Therefore, nanotechnology-

based drug delivery systems may not be widely used, especially in settings with limited resources, due to their potentially much higher production costs compared to standard drug delivery methods.[28]
Nanomaterials' possible toxicity and long-term safety is another major worry. Despite their many benefits, nanoparticles pose certain risks due to their tiny size and large surface area, which can cause cytotoxicity, immune system activation, or gradual buildup in organs. The potential for nanoparticles to have negative effects due to their unusual characteristics, such as their capacity to penetrate biological barriers like the blood-brain barrier, is cause for concern. To evaluate these systems' safety, in-depth toxicological investigations are necessary. However, a major concern for the broad clinical application of nanotechnology is the lack of knowledge about the long-term impacts of nanomaterials on the human body.[29]
Developing and approving drug delivery systems based on nanotechnology is complex, as there are currently no standardized testing methodologies and several regulatory impediments. There are currently no widely agreed-upon standards for assessing the quality, safety, and effectiveness of nanoparticles utilized in medication delivery, and regulatory bodies like the FDA and EMA are still adjusting to the novel aspects of nanomedicine. Each nanoparticle formulation may have to go through unique, thorough testing for toxicity, pharmacokinetics, and effectiveness prior to being approved for clinical use, which makes the approval process more complicated due to the lack of common testing methodologies. The development of pharmaceuticals based on nanotechnology can be costly and time-consuming due to the various regulatory hurdles that must be overcome.[30]
Nanotechnology has enormous promise for medication delivery, but there are still many obstacles to overcome before it can reach its full potential in clinical practice, including its high cost, possible toxicity issues, and regulatory and safety hurdles.[31]

**Case Studies and FDA-Approved Nanomedicines**

Several FDA-approved medicines exhibit the promise of nanomedicine in enhancing therapeutic results, and drug delivery systems based on nanotechnology have already shown considerable clinical success. Doxil®, which is doxorubicin in a liposomal form, and Abraxane®, which is paclitaxel in a nanoparticle albumin form, are two prominent examples. The 1995-approved medicine Doxil® encapsulates the chemotherapeutic chemical doxorubicin in liposomes, making it more soluble and lowering its toxicity to healthy tissues, including the heart. To further enhance efficacy and minimize side effects, the liposomal formulation makes use of the Enhanced Permeability and Retention (EPR) effect, which permits the medicine to concentrate in tumor tissues. Ovarian and breast tumors are among the many types of cancer that have responded well to Doxil®.[32]
Meanwhile, Abraxane®, which was approved in 2005, helps make paclitaxel more soluble and allows it to be delivered to tumor cells through albumin receptors. Breast, non-small cell lung, and pancreatic cancer patients can benefit from this formulation since it lessens the use of harmful solvents and hypersensitivity reactions. Doxil® and Abraxane®, two nanotechnology-enhanced cancer treatments, show how nanotechnology can improve medication delivery while lowering the risks of conventional chemotherapy. These examples of successful nanomedicines demonstrate the potential of nanotechnology to enhance treatment outcomes and patient efficacy; for example, Onivyde® (liposomal irinotecan) for pancreatic cancer and Marqibo® (liposomal vincristine) for leukemia. An increasing number of ailments, such as cancer, neurological problems, and infectious diseases, may be amenable to new treatments made possible by the rapid advancements in nanomedicine.[33]
The future of nanotechnology in drug delivery holds exciting prospects, driven by ongoing advancements and the integration of cutting-edge technologies. One of the most promising developments is the integration of artificial intelligence (AI) and nanotechnology for personalized medicine. AI can help optimize nanoparticle design, predict drug behavior, and identify the most effective treatments for individual patients. By analyzing vast amounts of data, AI can assist in tailoring nanomedicines to the unique genetic, molecular, and environmental characteristics of patients, allowing for more precise and effective therapies. This combination has the potential to revolutionize personalized treatment plans, enhancing therapeutic efficacy while minimizing side effects.[34]
Another key area of development is the advancement of biodegradable and eco-friendly nanomaterials. As concerns about the environmental impact of nanomaterials grow, there is increasing focus on developing nanoparticles that are not only safe for human use but also environmentally sustainable. Biodegradable polymers and naturally derived materials are being explored to replace synthetic and potentially harmful substances. These materials can degrade safely in the body or environment, reducing long-term toxicity and environmental accumulation, which is particularly important as nanomedicines become more widely used in clinical practice.[35]
Furthermore, the development of multifunctional nanocarriers is opening new possibilities for theranostics, a combined approach of therapy and diagnosis. These nanocarriers are engineered to carry both therapeutic agents (such as drugs or genetic material) and diagnostic tools (such as imaging agents or sensors) in a single nanoparticle. This dual functionality allows for the real-time monitoring of therapeutic responses and the ability to adjust treatment strategies dynamically. For example, nanoparticles could be used to deliver chemotherapy while

simultaneously enabling imaging to track drug delivery and assess treatment effectiveness. Such theranostic nanocarriers have the potential to improve treatment outcomes, reduce the need for separate diagnostic procedures, and allow for more personalized and timely interventions.[36]

The future of nanotechnology in drug delivery is poised for transformative growth, with the integration of AI, the development of sustainable nanomaterials, and the advent of multifunctional **theranostic** nanocarriers. These innovations promise to not only enhance the precision and effectiveness of treatments but also address key challenges such as environmental sustainability, personalized healthcare, and real-time monitoring of therapeutic outcomes.[37]

**Conclusion**

Nanotechnology holds immense potential to revolutionize drug delivery, offering more efficient, precise, and targeted treatments for a wide range of diseases. The advancements in nanocarriers, such as liposomes, dendrimers, and metallic nanoparticles, have significantly improved drug solubility, bioavailability, and therapeutic efficacy, while minimizing side effects and toxicity. However, challenges such as high development costs, potential long-term safety concerns, and regulatory hurdles remain, requiring continued research and innovation. The future of nanomedicine looks promising, with emerging trends like the integration of AI for personalized treatment, the development of biodegradable and eco-friendly nanomaterials, and the creation of multifunctional theranostic systems that combine therapy and diagnosis. As these technologies evolve, they hold the potential to transform healthcare, providing more effective, sustainable, and tailored therapies that could benefit patients worldwide.

**References**

---

[1] Lacalendola Tundisi, Louise & Artem Ataide, Janaina & Ribeiro Costa, Juliana & Coelho, Diego & Lopes, André & Oliveira-Nascimento, Laura & De Jesus, Marcelo & Jozala, Angela & Ehrhardt, Carsten & Mazzola, Priscila. (2022). Nanotechnology as a Tool to Overcome Macromolecules Delivery Issues. Colloids and Surfaces B: Biointerfaces. 222. 113043. 10.1016/j.colsurfb.2022.113043.

[2] Huma Ghazal, Aimen Waqar, Faiza Yaseen, Muhammad Shahid, Mahnoor Sultana, Mehlayl Tariq, Muhammad Kamran Bashir, Hira Tahseen, Tehreem Raza, Farooq Ahmad,Role of nanoparticles in enhancing chemotherapy efficacy for cancer treatment,Next Materials,Volume 2,2024,100128,ISSN 2949-8228, https://doi.org/10.1016/j.nxmate.2024.100128.

[3] Huang, Y., Guo, X., Wu, Y. et al. Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment. Sig Transduct Target Ther 9, 34 (2024). https://doi.org/10.1038/s41392-024-01745-z

[4] Chehelgerdi, M., Chehelgerdi, M., Allela, O.Q.B. et al. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer 22, 169 (2023). https://doi.org/10.1186/s12943-023-01865-0

[5] Joseph TM, Kar Mahapatra D, Esmaeili A, Piszczyk Ł, Hasanin MS, Kattali M, Haponiuk J, Thomas S. Nanoparticles: Taking a Unique Position in Medicine. Nanomaterials (Basel). 2023 Jan 31;13(3):574. doi: 10.3390/nano13030574. PMID: 36770535; PMCID: PMC9920911.

[6] Karthikeyan Elumalai, Sivaneswari Srinivasan, Anandakumar Shanmugam,
Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment,Biomedical Technology,Volume 5,2024,Pages 109-122,ISSN 2949-723X,https://doi.org/10.1016/j.bmt.2023.09.001.

[7] Malik S, Muhammad K, Waheed Y. Nanotechnology: A Revolution in Modern Industry. Molecules. 2023 Jan 9;28(2):661. doi: 10.3390/molecules28020661. PMID: 36677717; PMCID: PMC9865684.

[8] Malik S, Muhammad K, Waheed Y. Emerging Applications of Nanotechnology in Healthcare and Medicine. Molecules. 2023 Sep 14;28(18):6624. doi: 10.3390/molecules28186624. PMID: 37764400; PMCID: PMC10536529.

[9] Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin HS. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018 Sep 19;16(1):71. doi: 10.1186/s12951-018-0392-8. PMID: 30231877; PMCID: PMC6145203.

[10] Rema Sreenivasan Soumya, Kozhiparambil Gopalan Raghu,Recent advances on nanoparticle-based therapies for cardiovascular diseases,Journal of Cardiology,
Volume 81, Issue 1,2023,Pages 10-18,ISSN 0914-5087,https://doi.org/10.1016/j.jjcc.2022.02.009.

[11] Rahim MA, Jan N, Khan S, Shah H, Madni A, Khan A, Jabar A, Khan S, Elhissi A, Hussain Z, Aziz HC, Sohail M, Khan M, Thu HE. Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting. Cancers (Basel). 2021 Feb 7;13(4):670. doi: 10.3390/cancers13040670. PMID: 33562376; PMCID: PMC7914759.

[12] Guimarães D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021 May 15;601:120571. doi: 10.1016/j.ijpharm.2021.120571. Epub 2021 Apr 2. PMID: 33812967.
[13] Seidu TA, Kutoka PT, Asante DO, Farooq MA, Alolga RN, Bo W. Functionalization of Nanoparticulate Drug Delivery Systems and Its Influence in Cancer Therapy. Pharmaceutics. 2022 May 23;14(5):1113. doi: 10.3390/pharmaceutics14051113. PMID: 35631699; PMCID: PMC9145684.
[14] Preeti, Sambhakar S, Malik R, Bhatia S, Al Harrasi A, Rani C, Saharan R, Kumar S, Geeta, Sehrawat R. Nanoemulsion: An Emerging Novel Technology for Improving the Bioavailability of Drugs. Scientifica (Cairo). 2023 Oct 28;2023:6640103. doi: 10.1155/2023/6640103. PMID: 37928749; PMCID: PMC10625491.
[15] Pinho Melo, Eduardo & Aires-Barros, Maria & Cabral, Joaquim. (2001). Reverse micelles and protein biotechnology. Biotechnology annual review. 7. 87-129. 10.1016/S1387-2656(01)07034-X.
[16] Negut I, Bita B. Polymeric Micellar Systems-A Special Emphasis on "Smart" Drug Delivery. Pharmaceutics. 2023 Mar 17;15(3):976. doi: 10.3390/pharmaceutics15030976. PMID: 36986837; PMCID: PMC10056703.
[17] Zhuo, Y., Zhao, Y. -G., & Zhang, Y. (2024). Enhancing Drug Solubility, Bioavailability, and Targeted Therapeutic Applications through Magnetic Nanoparticles. Molecules, 29(20), 4854. https://doi.org/10.3390/molecules29204854
[18] Chou-Yi Hsu, Ahmed Mahdi Rheima, Mustafa M. Kadhim, Nada Nadhim Ahmed, Srwa Hashim Mohammed, Fatima Hashim Abbas, Zainab Talib Abed, Zahra Muhammed Mahdi, Zainab Sabri Abbas, Safa K. Hachim, Farah K. Ali, Zaid H Mahmoud, Ehsan Kianfar,An overview of nanoparticles in drug delivery: Properties and applications,South African Journal of Chemical Engineering,Volume 46,2023,Pages 233-270,ISSN 1026-9185,https://doi.org/10.1016/j.sajce.2023.08.009.
[19] Prajapati, A., Rangra, S., Patil, R., Desai, N., Jyothi, V. G. S. S., Salave, S.,Amate, P., Benival, D., & Kommineni, N. (2024). Receptor-TargetedNanomedicine for Cancer Therapy. Receptors, 3(3), 323-361.https://doi.org/10.3390/receptors3030016
[20] A.L.B. Seynhaeve, M. Amin, D. Haemmerich, G.C. van Rhoon, T.L.M. tenHagen,Hyperthermia and smart drug delivery systems for solid tumor therapy,
Advanced Drug Delivery Reviews,Volumes 163–164,2020,Pages 125-144,
ISSN 0169-409X,https://doi.org/10.1016/j.addr.2020.02.004.
[21] Cheng X, Xie Q, Sun Y. Advances in nanomaterial-based targeted drug delivery systems. Front Bioeng Biotechnol. 2023 Apr 13;11:1177151. doi: 10.3389/fbioe.2023.1177151. PMID: 37122851; PMCID: PMC10133513.
[22] Maria Inês Teixeira, Carla M. Lopes, Maria Helena Amaral, Paulo C. Costa,
Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): A current overview of active targeting in brain diseases,Colloids and Surfaces B:Biointerfaces,Volume 221,2023,112999,ISSN 0927-7765,
https://doi.org/10.1016/j.colsurfb.2022.112999.
[23] Hetta HF, Ramadan YN, Al-Harbi AI, A Ahmed E, Battah B, Abd Ellah NH, Zanetti S, Donadu MG. Nanotechnology as a Promising Approach to Combat Multidrug Resistant Bacteria: A Comprehensive Review and Future Perspectives. Biomedicines. 2023 Jan 31;11(2):413. doi: 10.3390/biomedicines11020413. PMID: 36830949; PMCID: PMC9953167.
[24] Dubey AK, Mostafavi E. Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy. Front Chem. 2023 Sep 28;11:1259435. doi: 10.3389/fchem.2023.1259435. PMID: 37841202; PMCID: PMC10568484.
[25] Tobechukwu Christian Ezike, Ugochukwu Solomon Okpala, Ufedo Lovet Onoja, Chinenye Princess Nwike, Emmanuel Chimeh Ezeako, Osinachi Juliet Okpara, Charles Chinkwere Okoroafor, Shadrach Chinecherem Eze, Onyinyechi Loveth Kalu, Evaristus Chinonso Odoh, Ugochukwu Gideon Nwadike, John Onyebuchi Ogbodo, Bravo Udochukwu Umeh, Emmanuel Chekwube Ossai, Bennett Chima Nwanguma,Advances in drug delivery systems, challenges and future directions,
Heliyon,Volume 9, Issue 6,2023,e17488,
ISSN 2405-8440,https://doi.org/10.1016/j.heliyon.2023.e17488.
[26] Andrea Luraghi, Francesco Peri, Lorenzo Moroni,Electrospinning for drug delivery applications: A review,Journal of Controlled Release,Volume 334,
2021,Pages 463-484,ISSN 0168-3659,https://doi.org/10.1016/j.jconrel.2021.03.033.
[27] Patra, J.K., Das, G., Fraceto, L.F. et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol 16, 71 (2018). https://doi.org/10.1186/s12951-018-0392-8
[28] Sim S, Wong NK. Nanotechnology and its use in imaging and drug delivery (Review). Biomed Rep. 2021 May;14(5):42. doi: 10.3892/br.2021.1418. Epub 2021 Mar 5. PMID: 33728048; PMCID: PMC7953199.

[29] Xuan L, Ju Z, Skonieczna M, Zhou PK, Huang R. Nanoparticles-induced potential toxicity on human health: Applications, toxicity mechanisms, and evaluation models. MedComm (2020). 2023 Jul 14;4(4):e327. doi: 10.1002/mco2.327. PMID: 37457660; PMCID: PMC10349198.

[30] Prashant Pingale, Prakash Kendre, Krutika Pardeshi, Amarjitsing Rajput,
An emerging era in manufacturing of drug delivery systems: Nanofabrication techniques,Heliyon,Volume 9, Issue 3,2023,e14247,ISSN 2405-8440,
https://doi.org/10.1016/j.heliyon.2023.e14247.

[31] Egwu, C.O.; Aloke, C.; Onwe, K.T.; Umoke, C.I.; Nwafor, J.; Eyo, R.A.; Chukwu, J.A.; Ufebe, G.O.; Ladokun, J.; Audu, D.T.; et al. Nanomaterials in Drug Delivery: Strengths and Opportunities in Medicine. Molecules 2024, 29, 2584. https://doi.org/10.3390/molecules29112584

[32] Nirmala MJ, Kizhuveetil U, Johnson A, G B, Nagarajan R, Muthuvijayan V. Cancer nanomedicine: a review of nano-therapeutics and challenges ahead. RSC Adv. 2023 Mar 14;13(13):8606-8629. doi: 10.1039/d2ra07863e. PMID: 36926304; PMCID: PMC10013677.

[33] Yuan H, Guo H, Luan X, He M, Li F, Burnett J, Truchan N, Sun D. Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer. Mol Pharm. 2020 Jul 6;17(7):2275-2286. doi: 10.1021/acs.molpharmaceut.9b01221. Epub 2020 Jun 17. PMID: 32485107; PMCID: PMC8829889.

[34] M.O. Ori, F.M. Ekpan, H.S. Samuel, O.P. Egwuatu, Integration of Artificial Intelligence inNanomedicine. Eurasian J. Sci. Technol., 2024, 4(2), 88-104.

[35] Abdul Wahab, Murad Muhammad, Shahid Ullah, Gholamreza Abdi, Ghulam Mujtaba Shah, Wajid Zaman, Asma Ayaz,Agriculture and environmental management through nanotechnology: Eco-friendly nanomaterial synthesis forsoil-plant systems, food safety, and sustainability,Science of The Total Environment,Volume 926,2024,171862,ISSN 0048-9697,
https://doi.org/10.1016/j.scitotenv.2024.171862.

[36] S.M. Hosseini, J. Mohammadnejad, S. Salamat, Z. Beiram Zadeh, M. Tanhaei, S. Ramakrishna,Theranostic polymeric nanoparticles as a new approach in cancer therapy and diagnosis: a review,Materials Today Chemistry,
Volume 29,2023,101400,ISSN 2468-5194,https://doi.org/10.1016/j.mtchem.2023.101400.

[37] David B. Olawade, Abimbola O. Ige, Abimbola G. Olaremu, James O. Ijiwade, Adedapo O. Adeola,The synergy of artificial intelligence and nanotechnology towards advancing innovation and sustainability - A mini-review,Nano Trends,
Volume 8,2024,100052,ISSN 2666-9781,https://doi.org/10.1016/j.nwnano.2024.100052.